The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs

[cujoe]

Only vaguely familiar to me (mostly due to the original mustachio moniker), the Movember Foundation is a non-profit organization dedicated to men's health issues. It started in AU in 2003 and has expanded since to be a top world-wide NGO. Here is a link to their website and the story of its humble beginnings and growth over time:

us.movember.com/about/history

This quite small survey study (only 9 PCa patients) by their organization is still interesting for the issues defined and the specific research priorities assigned.

Abstract

Prostate cancer is a heterogeneous cancer with widely varying levels of morbidity and mortality. Approaches to prostate cancer screening, diagnosis, surveillance, treatment and management differ around the world. To identify the highest priority research needs across the prostate cancer biomedical research domain, Movember conducted a landscape analysis with the aim of maximizing the effect of future research investment through global collaborative efforts and partnerships. A global Landscape Analysis Committee (LAC) was established to act as an independent group of experts across urology, medical oncology, radiation oncology, radiology, pathology, translational research, health economics and patient advocacy. Men with prostate cancer and thought leaders from a variety of disciplines provided a range of key insights through a range of interviews. Insights were prioritized against predetermined criteria to understand the areas of greatest unmet need. From these efforts, 17 research needs in prostate cancer were agreed on and prioritized, and 3 received the maximum prioritization score by the LAC: first, to establish more sensitive and specific tests to improve disease screening and diagnosis; second, to develop indicators to better stratify low-risk prostate cancer for determining which men should go on active surveillance; and third, to integrate companion diagnostics into randomized clinical trials to enable prediction of treatment response. On the basis of the findings from the landscape analysis, Movember will now have an increased focus on addressing the specific research needs that have been identified, with particular investment in research efforts that reduce disease progression and lead to improved therapies for advanced prostate cancer.

Full paper is here:

nature.com/articles/s41585-...

Be Well - K9

[NPfisherman]

K9 Terror,

Thanks for posting...

The new testing is developing so rapidly with mRNA urine test which can find the cancer much earlier than the PSA....It was interesting reading and the focus for Movember seems to be on earlier detection and treatment...Currently, there are 303 Prostate cancer trials at the NCI ....There are newer radiotracers, new checkpoint inhibitors, new vaccines, new classes of drugs being tested here and abroad...When I tested in 2018, the Axumin scan was the best approved scan....in 2 years radiotracers have advanced and there are trials for radiotracers likely better than the Ga68 PSMA scans... just amazing...

Don Pescado